DAY 1   

THURSDAY 29 MAY 2008

8.00am

Registration and Morning Coffee

8.50am

Conference Chairman’s Welcome Address and Opening Remarks

Critical accounting issues as they relate to current business climate will be addressed. In particular, newest issues in the pharmaceutical, biotechnology and life sciences industries and their impact on future business plans will be highlighted.

9.10am

Valuing Intangibles and Impairment Testing in the Pharmaceutical Industry

·          Approaches for valuing intangible assets in an acquisition

·          Approaches to subsequent impairment tests, both for goodwill and other intangibles

Mr Lars Barslev, Partner, Vanden Advisors LLP, Singapore

9.55am

Accounting for Share Based Payments and Other Compensation Issues

·          Share Based Payment Valuations

·          Implications for Long Term Incentive (LTI) Design

·          Perfecting your LTIs

·          Governance and Regulatory Impact on Executive Compensation

·          Key Executive Compensation Trends

Mr Derek Berry, Business Leader – Human Capital, ASEAN, Mercer , Singapore

10.10am

Coffee Break

11.10am

Case Study: Understanding India

12.00pm

Best Practices in Strategic Deals and Collaborations

·          Understanding the rationale for deals & collaborations

·          Negotiating strategic deals

·          Types of Deals- License agreements, Joint Ventures, Acquisitions

·          Contractual terms and considerations

·          Due diligence process

Ms Audrey Yap, Managing Partner, Yu Sarn Audrey & Partners , Singapore

12.45pm

Conference Luncheon

2.10pm

Investment Opportunities in Healthcare in Greater China in the Near-Term Future

·          Overview of healthcare landscape in Greater China

·          Recent stock performance of listed healthcare companies in China

·          Survey of recent healthcare IPO’s and M&A’s in Greater China

·          Comparison with select US and Asia companies in healthcare

·          Comparison with India healthcare landscape

·          Near term trends in medical devices, services and biopharmaceuticals in Greater China

Mr George Lin, Head of Non-Japan Asia Healthcare Investment Banking, Credit Suisse ( Hong Kong ) Limited, Hong Kong

3.00pm

Being the Best – Insights from Leading Finance Functions

·          Key differentiators of leading finance functions – can these be replicated in other organizations?

·          Balancing the demands of the internal business with external stakeholders and regulatory bodies

·          How to overcome barriers to achieving leading practices

·          What does a future finance department look like?

Mr Aman Kumar, Manager, Business Performance Services, KPMG Advisory Services Pte Ltd, Singapore

3.45pm

Coffee Break

4.05pm

IFRS – Its Development, Implication and Impact on the Pharmaceutical Industry

·          How global financial markets are driving the trend toward IFRS

·          SEC vote to remove reconciliation requirement

·          Implication of trend toward IFRS on pharmaceutical industry

·          Significant differences about financial reporting and disclosure requirements

·          What is actually involved in conversion

Mr Lee Chian Yorn, Partner, PricewaterhouseCoopers , Singapore

4.50pm

Transfer Pricing Issues in the Pharmaceutical Industry

·          Industry trends

·          Developing strong internal controls for Transfer Pricing

·          What NOT to share in a TP report

·          Practical issues/ strategies

Mr Mukesh Butani, Partner, BMR & Associates, India

5.35pm

Close of Day One

DAY 2    

FRIDAY 30 MAY 2008

9.00am

Conference Chairman’s Opening Remarks

9.05am

The Changing CFO Role: From Keeping the Score to Shaping the Play

·          Key drivers to the changing role

·          Shift in focus: Financial Control Systems, Risk Management, Regulatory Compliance, Financial Analysis and Reporting, Development of Corporate Strategy, Performance Management Systems

·          Investments in business support technology solutions to achieve business goals

·          Transparency and communication with investors

·          Balancing the changing demands and maintaining performance standards

Ms Lay Peng Tan, Financial Controller, Pfizer Worldwide Pharmaceutical Operations, Singapore

9.55am

A Risk Centric Internal Audit Model

·          Effectiveness of assurance from risk management in addition to internal controls

Mr Rajan Ekambaram, Partner, Ernst & Young , Singapore

10.35m

Coffee Break

11.00am

Protecting Pharmaceutical Companies against Fraud and Misconduct Risks

·          Benefits and elements of an effective anti-fraud program

·          Fraud and misconduct risk assessments

·          Fraud schemes common to the pharmaceutical industry

Mr Peter Coleman, Principal, Head – Forensic Services, Singapore and Southeast Asia , Deloitte & Touche Financial Advisory Services Pte Ltd, Singapore

11.45am

Security and Shareholder Liability Risk Issues

·          Obligations and good practices

·          How to mitigate securities and shareholder litigation risks

·          Insurance and indemnity to protect co-officers/directors from personal liability

Ms Aruno Rajaratnam, Managing Director, Willis Asia, Singapore

12.30pm

Conference Luncheon

2.00pm

New Regulations in Sales and Marketing Reporting Compliance

·          Interactions with healthcare professionals

-          Events including foreign travel

-          Sponsorship

-          Hospitality

-          Entertainment

-          Gifts and promotional items

·          Responsibilities of pharmaceutical-healthcare professionals-patient relationship

·          Transparency of promotion

·          Standards of promotional information

·          Disguised and misleading promotion

·          Compliance programme development

·          Risk assessment

Mr Chris McNamara, Asia Pacific Controller, Merck & Co., Inc., Singapore

2.45pm

Forum on Sales and Marketing Reporting Compliance: Healthcare – Pharma – Patient Associations

Mr Chris McNamara, Asia Pacific Controller, Merck & Co., Inc., Singapore

Are patients paying more than necessary for their drugs?

Ms M K Fatimah, Head of Pharmacy Department, Alexandra Hospital , Member of Consumer Education Committee, Consumer Association of Singapore (CASE), Singapore

and  other panelists from Healthcare and Patient Associations to be advised

3.15pm

Coffee Break

3.40pm

Using Compliance Management to Overcome Financial and Reputation Risks in the Pharma Industry

·          Challenges in complying to multiple regulations – increasing complexity and costs

·          Elements of a sustainable compliance framework to maintain brand value

·          How to implement a cost-effective and sustainable compliance regime

·          Use of compliance technologies

Mr Philip Chong, Director, Enterprise Risk Services, Deloitte & Touche, Singapore

4.25pm

Looking Ahead: Outlook and Challenges for the Future

(All speakers and delegates are invited)

4.55pm

Chairman’s Closing Remarks

5.00pm

End of Conference